Enliven Therapeutics, Inc.

NASDAQ•ELVN

CEO: Mr. Samuel S. Kintz M.B.A.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2020-03-12

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Contact Information

6200 Lookout Road, Boulder, CO, 80301, United States

720-647-8519

www.enliventherapeutics.com

Market Cap

$1.86B

P/E (TTM)

-17.0

17.4

Dividend Yield

52W High

$31.76

52W Low

$13.30

52W Range

97%

Rank51Top 71.3%

3.0

F-Score

Modified Piotroski Analysis

Based on 8-year fundamentals

Weak • 3 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2018-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.45+0.00%

4-Quarter Trend

FCF

-$15.84M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Strong Cash Position Cash, equivalents, and marketable securities totaled $462.6M as of Dec 31, 2025, providing sufficient funding for operations into the first half of 2029.

ELVN-001 Clinical Progress Phase 1 ENABLE trial reported 47% cumulative MMR rate by 24 weeks; Phase 3 pivotal trial initiation planned for the second half of 2026.

Successful Capital Raising Completed public offering in June 2025, raising $216.2M net proceeds to support ongoing clinical development and general corporate activities for the company.

Risk Factors

Significant Operating Losses Net loss $103.7M for 2025; accumulated deficit $347.2M; no revenue generated to date, with significant operating losses expected to continue for foreseeable future.

Clinical Development Uncertainty ELVN-001 success depends on Phase 3 trial outcomes; failure to demonstrate safety or efficacy would materially harm business prospects and future viability.

Regulatory Approval Hurdles Lengthy, unpredictable FDA/EMA approval processes; potential for clinical holds or requirements for additional studies could delay commercialization and impact future revenue generation.

Manufacturing Supply Risks Reliance on third-party CMOs for drug supply; potential for supply disruptions or failure to meet cGMP standards could delay clinical trial timelines.

Outlook

Advance ELVN-001 Program Prioritize clinical development of ELVN-001; plan to initiate ENABLE-2, a 2L+ Phase 3 pivotal trial in the second half of 2026.

Strategic Resource Allocation Discontinued ELVN-002 development to focus resources on ELVN-001; currently exploring strategic alternatives for the ELVN-002 program to maximize portfolio value.

Future Capital Requirements Expect increased expenses for clinical trials and operations; will require additional funding to support long-term development and commercialization goals for product candidates.

Peer Comparison

Revenue (TTM)

SNDX

$172.35M

+627.8%

SYRE

$90.49M

+0.0%

CVAC

$78.57M

-87.0%

Gross Margin (Latest Quarter)

ATAI

1021.8%

+0.0pp

SNDX

102.3%

-13.9pp

DNTH

100.0%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
DNTH	$2.84B	0.0	0.0%	0.3%
SYRE	$2.55B	-94.1	-29.4%	0.0%
WVE	$2.19B	-10.3	-85.0%	2.8%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 12, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data